Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Entera Bio Ltd

ENTX
Current price
2.07 USD -0.01 USD (-0.48%)
Last closed 2.08 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 74 791 272 USD
Yield for 12 month +149.40 %
1Y
3Y
5Y
10Y
15Y
ENTX
21.11.2021 - 28.11.2021

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Address: Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10 USD

P/E ratio

Dividend Yield

Current Year

+14 000 USD

Last Year

+134 000 USD

Current Quarter

Last Quarter

+4 482 000 USD

Current Year

-56 000 USD

Last Year

+33 000 USD

Current Quarter

-13 000 USD

Last Quarter

+4 469 000 USD

Key Figures ENTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -8 686 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -50.02 %
PEG Ratio
Return On Equity TTM -92.02 %
Wall Street Target Price 10 USD
Revenue TTM 14 000 USD
Book Value 0.25 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -91.5 %
Dividend Yield
Gross Profit TTM 33 000 USD
Earnings per share -0.28 USD
Diluted Eps TTM -0.28 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ENTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ENTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ENTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3207.1297
Price Sales TTM 107.2532
Enterprise Value EBITDA -10.7646
Price Book MRQ 10.1805

Financials ENTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ENTX

For 52 weeks

0.52 USD 3.35 USD
50 Day MA 2.23 USD
Shares Short Prior Month 127 010
200 Day MA 1.2 USD
Short Ratio 0.57
Shares Short 91 368
Short Percent 0.4 %

Dynamics of changes in the value of assets

Stocks


AAPL

AAPL

212.49 USD Apple Inc -1.32 (-0.62%)
Detailed analytics

ETF funds


S

SX7EEX

13.36 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.53 (-3.54%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics